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Highlights  
 RNA-sequencing of a prostate cancer cell line and 7 prostate cancer patients 
identifies a core set of 700 clinically relevant androgen-regulated genes. 
 Glycosylation is a global target for androgen control in prostate cancer cells. 
 A set of 8 glycosylation enzymes are important for prostate cancer cell viability. 
 
Research in context 
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Androgen steroid hormones including testosterone drive the growth of and are the principal 
targets for treating prostate cancer. This makes genes and pathways under androgen control 
clinically important. Here we find androgens control patterns of glycosylation in prostate 
cancer cells. Glycosylation is the addition of sugar groups to proteins, which can change the 
function and localisation of modified proteins and plays an important role in all stages of 
cancer. We particularly identify 8 key androgen-controlled glycosylation enzymes that 
frequently change expression in prostate cancer, and find these enzymes are important 
cancer cell survival and so could be targeted therapeutically. 
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Abstract  
Steroid androgen hormones play a key role in the progression and treatment of prostate 
cancer, with androgen deprivation therapy being the first-line treatment used to control 
cancer growth. Here we apply a novel search strategy to identify androgen-regulated cellular 
pathways that may be clinically important in prostate cancer. Using RNASeq data, we 
searched for genes that showed reciprocal changes in expression in response to acute 
androgen stimulation in culture, and androgen deprivation in patients with prostate cancer. 
Amongst 700 genes displaying reciprocal expression patterns we observed a significant 
enrichment in the cellular process glycosylation. Of 31 reciprocally-regulated glycosylation 
enzymes, a set of 8 (GALNT7, ST6GalNAc1, GCNT, UAP1, PGM3, CSGALNACT1, 
ST6GAL1 and EDEM3) were significantly up-regulated in clinical prostate carcinoma. 
Androgen exposure stimulated synthesis of glycan structures downstream of this core set of 
regulated enzymes including sialyl-Tn (sTn), sialyl LewisX (SLeX), O-GlcNAc and chondroitin 
sulphate, suggesting androgen regulation of the core set of enzymes controls key steps in 
glycan synthesis. Expression of each of these enzymes also contributed to prostate cancer 
cell viability. This study identifies glycosylation as a global target for androgen control, and 
suggests loss of specific glycosylation enzymes might contribute to tumour regression 
following androgen depletion therapy. 
Abstract word count: 199 
Manuscript word count: 10,402  
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Introduction 
Prostate cancer (PCa) is the second most common cause of male cancer death in the 
United States, and there is an urgent need to identify the key mechanisms that drive clinical 
disease progression and its response to treatment, biomarkers for disease progression and 
therapeutic targets. Male steroid hormones called androgens play a critical role in PCa 
progression, and androgen deprivation therapy (ADT) is the first line treatment for PCa. 
Although ADT is usually initially effective, many patients ultimately develop lethal castrate-
resistant PCa (CRPCa) for which treatment options are limited. Androgens control gene 
expression via a transcription factor called the androgen receptor (AR). The AR is essential 
for PCa cell viability, proliferation and invasion (Snoek et al., 2009, Hara et al., 2008, Haag 
et al., 2005), and in CRPCa there is a strong selective pressure on cells to maintain AR-
regulated signalling pathways even in lower conditions of circulating androgens. Progression 
to CRPCa is thought to involve persistence of AR signalling and reprogramming of the AR 
transcriptional landscape (Sharma et al., 2013, Mills, 2014), during which time AR activity is 
maintained through activating mutations (Veldscholte et al., 1990, Steinkamp et al., 2009), 
gene amplification (Visakorpi et al., 1995), AR splice variants (Sun et al., 2010), or signalling 
crosstalk with other oncogenic pathways (Craft et al., 1999).  
Classically, androgen binding is thought to promote dimerization of AR and its 
translocation to the nucleus where it can act as either a transcriptional enhancer or 
repressor, depending on the target gene (Karantanos et al., 2013, Cai et al., 2011). Various 
genomic and transcriptomic approaches have been used to identify both AR binding sites 
and target genes. However, these studies have generally focused either on the use of a 
single model of prostate cancer (LNCaP or its in vitro derived subclones) (Massie et al., 
2007, Wang et al., 2007, Rajan et al., 2011),  only on AR regulated genes with nearby AR 
genomic binding sites (Massie et al., 2011, Sharma et al., 2013), or have been limited by 
genome coverage on microarrays (Rajan et al., 2011, Massie et al., 2007, Massie et al., 
2011, Wang et al., 2009a). Genome-wide mapping of AR binding was recently achieved in 
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prostate tissue using chromatin immunoprecipitation sequencing (ChIP-seq) (Sharma et al., 
2013). This study successfully revealed an in vivo  AR regulated transcriptional program in 
CRPCa (Sharma et al., 2013), but was limited by the challenges of directly associating an 
AR binding site with a given gene and its expression (Barfeld et al., 2014, Wu et al., 2011). 
Recent RNA-Seq analysis of metastatic CRPCa revealed that the majority of 
metastatic PCa harbours clinically actionable molecular alterations (Robinson et al., 2015), 
providing hope for precision medicine in affected individuals. However, despite this finding, 
the mechanisms through which androgens drive the initial development and growth of PCa 
remain poorly understood. To address these issues we used RNA-Seq to comprehensively 
profile how the PCa transcriptome responds to androgens. Since previous studies have 
demonstrated the importance of cellular context in the functional positioning of the AR 
(Sharma et al., 2013), we directly correlated this gene expression data after androgen 
stimulation with RNA-Seq data from 7 PCa patients before and after receiving ADT (Rajan et 
al., 2014). This combined approach identified a core set of nearly 700 genes which were 
reciprocally regulated between the two datasets and so are strong candidates for being 
clinically relevant androgen-regulated genes within localised cancers. Gene-set enrichment 
of these 700 genes revealed a multi-factorial link between androgens and the PCa 
glycoproteome, and specifically a core group of 7 glycosylation enzymes that significantly 
change expression in clinical PCa. Importantly, within this core set, 6 enzymes have not 
previously been implicated in PCa. Our data suggest that androgen regulation of these 8 
core enzymes may be rate limiting for the expression of cancer-associated glycans and 
suggests loss of glycosylation enzymes might contribute to tumour regression following ADT.  
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Materials and Methods 
 
RNA-Seq and analysis 
For RNA-Seq of LNCaP cells: RNA was prepared for sequencing using a RNA Easy Kit 
(Qiagen 74104). All RNA samples were DNase I treated using a DNA-free kit (Invitrogen) 
and stored at −80 °C prior to RNA quality control check using 2100 Agilent Bioanalyser and 
mRNA library prep using TruSeq mRNA library kit (Illumina). Pair-end sequencing was done 
in total for six samples (three biological replicates of LNCaP cells grown in charcoal stripped 
steroid deplete media, and three biological replicates from LNCaP cells grown in the 
presence of 10nM R1881 for 24h) using an Illumina HiSeq 2000. RNA-Seq of RNA from 7 
patients before and after ADT (Clinical dataset A) was as described previously (Rajan et al., 
2014). Expression distribution, scatter and volcano polts for both RNA-Seq datasets are 
shown in Supplementary Figures 2a & 2b.  
The RNA-Seq analysis of both datasets was carried out as follows: Differential gene 
and transcript expression analysis was performed according to the Tuxedo protocol  
(Trapnell et al., 2012). Separately for each of the clinical (7 patients pre- and post ADT, 
clinical cohort A), and cell-line samples (LNCaP cells grown with or without androgens), all 
reads were first mapped to human transcriptome/genome (build hg19) with TopHat (Kim et 
al., 2013) /Bowtie (Langmead and Salzberg, 2012), followed by per-sample transcript 
assembly with Cufflinks (Trapnell et al., 2013). Transcript assemblies derived from the 
clinical samples were merged together with Cuffmerge (Trapnell et al., 2013), and differential 
expression between the two conditions (prior and post androgen-deprivation therapy) was 
assessed with Cuffdiff (Trapnell et al., 2013). Genes/isoforms labelled by the software as 
significantly differentially expressed were extracted from the results. The mapped LNCaP 
data was processed with the same pipeline (with Cuffmerge, Cuffdiff and Cuffcompare, 
followed by extraction of significantly differentially expressed genes/isoforms); in this case, 
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expression changes between cells grown with or without androgens were assessed. Two 
subsets of significantly differentially expressed genes were identified: 1) Genes up-regulated 
by androgens in LNCaP cells and down-regulated in 7 patients following androgen-
deprivation therapy. 2) Genes down-regulated by androgens in LNCaP cells and up-
regulated in 7 patients following androgen-deprivation therapy. 
 
Gene Ontology Analysis 
GO analysis was carried out as described previously (Young et al., 2010). Enrichment of GO 
biological processes (with <500 annotations) was calculated using the goseq R package 
(version 1.18.0).  Genes were considered significant at a p-value threshold of 0.05 after 
adjustment using the Benjamini-Hochberg false discovery rate. 
 
Antibodies 
The antibodies and lectins used in the study are listed in Supplementary Table 1. The 
specificity of all of the antibodies used was validated by siRNA mediated protein depletion 
(Supplementary Figure 2).  
 
Cell culture 
Cell culture and the cell lines used were as described previously (Munkley et al., 2014, 
Munkley et al., 2015a, Munkley et al., 2015b, Munkley et al., 2015c). All siRNA sequences 
are listed in Supplementary Table 1.   
 
Clinical Samples 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
8 
 
Clinical dataset A: The patient samples used for RNA-Sequencing were as described 
previously (Rajan et al., 2014). RNA was obtained from seven patients with locally advanced 
metastatic prostate cancer before and ~22 weeks after ADT.  The clinical samples used in 
clinical datasets B and C are as described previously (Munkley et al., 2015c, Munkley et al., 
2015b). The samples were obtained with ethical approval through the Exeter NIHR Clinical 
Research Facility tissue bank (Ref: STB20). Written informed consent for the use of 
surgically obtained tissue was provided by all patients. 
 
RT-qPCR 
RT-qPCR was carried out as described previously (Munkley et al., 2015c). All primer 
sequences are listed in Supplementary Table 1. 
 
Cell viability analysis 
Cell viability analysis was carried out using the TaliR Cell Viability Kit (Life Technologies 
A10786) and the TaliR Image-based Cytometer. Relative cell numbers following siRNA 
treatment were determined using the TaliR Image-based Cytometer (Life Technologies). 
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Results 
Reciprocal gene expression patterns identify a core set of clinically relevant 
androgen-regulated target genes  
To analyse how the PCa transcriptome globally responds to androgens we carried out 
triplicate RNA-Seq of LNCaP cells grown with or without 10nM R1881 (a synthetic androgen) 
in vitro for 24 hours. This procedure identified 3,339 genes which were significantly up-
regulated by androgens, and 2,760 genes which were significantly down-regulated (q<0.05) 
(Supplementary Tables 2 & 3). Since previous studies have demonstrated a divergence 
between in vivo and in vitro AR-regulated genes (Sharma et al., 2013), we correlated our cell 
line data with RNA-Seq data from 7 PCa patients before and after ADT(clinical dataset A) 
(Rajan et al., 2014). This process identified nearly 700 potentially clinically relevant AR 
target genes that showed reciprocal expression signatures, indicating that they are both 
androgen regulated in culture and have reverse expression switches in patients in response 
to clinical ADT (Figure 1A, B). 
 
Glycosylation is a key cellular process regulated by the AR 
This comprehensive map of AR-regulated genes in clinical prostate cancer provides a new 
window through which to understand of the essential signalling pathways downstream of the 
AR and of the role these pathways play in both the development of PCa and the response to 
ADT. Within our dataset of 700 reciprocally regulated genes were many established classes 
of AR target genes, including cell cycle regulators (e.g. ORC5L), signalling molecules 
implicated in PCa (e.g. HER3), and genes with roles in central metabolism and biosynthetic 
pathways (e.g. CAMKK2), as well as many additional novel androgen-regulated genes 
(Supplementary Tables 4 & 5). Gene Ontology (GO) analysis of these 700 genes identified 
known AR regulated processes including lipid and cholesterol biosynthesis (Wu et al., 2014, 
Suburu and Chen, 2012, Swinnen et al., 1997b), fatty acid metabolism (Swinnen et al., 
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1997a, Swinnen et al., 2000, Liu, 2006), and response to ER stress (Segawa et al., 2002, 
Sheng et al., 2015) (Supplementary Table 6). Also, in addition to these previously known 
androgen-regulated cellular processes, ‘glycosylation’ was specifically identified as a 
previously unidentified androgen-regulated process, with a significant enrichment of genes 
encoding glycosylation enzymes within the dataset (Figure 1C).  
As mounting evidence links changes in the glycan composition of PCa cells to 
disease progression (Chen et al., 2014, Itkonen and Mills, 2013, Itkonen et al., 2014, 
Munkley et al., 2015c, Munkley et al., 2016), we further analysed our RNA-Seq data to 
identify 31 individual genes encoding glycosylation enzymes that display reciprocal gene 
expression between androgen stimulation in vitro, and ADT in patients (Figure 2A,B). Meta-
analysis of publically available clinical gene expression data across 326 samples in 3 large 
datasets (Taylor et al., 2010, Varambally et al., 2005, Grasso et al., 2012), and into two 
independent clinical RNA datasets, further resolved a subset of glycosylation genes that are 
additionally significantly up-regulated in PCa relative to the normal prostate gland (p<0.05) 
(Supplementary Table 7). These genes are shown in red in Figure 2A,B. Of these genes, 
UAP1 and ST6GalNAc1 are known AR target genes that have previously been linked with 
PCa progression (Itkonen et al., 2014, Munkley et al., 2015c, Munkley and Elliott, 2016b). 
However, to the best of our knowledge, this study is the first time that androgen-regulation of 
the other 6 genes (GCNT1, GALNT7, PGM3, CSGALNACT1, ST6GAL1, and EDEM3) has 
been described. Each of these 6 newly identified AR-regulated glycosylation enzyme genes 
showed a rapid pattern of activation following androgen stimulation in culture, suggesting 
they are early targets of the AR (Figure 2C). Consistent with them being physiological 
targets of the AR, transcription of these genes was also activated by a range of R1881 
concentrations, and inhibited by the AR antagonist Casodex® (Supplementary Figure 3). We 
also confirmed androgen-regulation of all 8 glycosylation enzymes in the androgen-
responsive VCaP prostate cancer cell line (Supplementary Figure 4). 
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Our meta-analysis made use of two independent clinical RNA validation cohorts, 
which were analysed using real-time PCR. The first cohort compared RNA samples of 
benign prostatic hyperplasia (BPH) versus prostate carcinoma obtained from 49 patients 
(clinical dataset B) (Figure 3A), and the second cohort compared carcinoma versus adjacent 
normal tissue within 9 patients (clinical dataset C) (Figure 3B). 7 out of the 8 glycosylation 
enzyme genes examined were significantly up-regulated in at least one of these two cohorts, 
with 5 genes (ST6GalNAc1, GALNT7, UAP1, CSGALNACT1 and EDEM3) significantly up-
regulated in both cohorts (p<0.05) (Supplementary Table 7). 
Further analysis of our cohort of patient tissue RNA from carcinoma versus normal 
tissue (clinical dataset C) also showed that several of the 8 glycosylation genes often 
changed expression in parallel, with the majority of patients showing a concurrent change in 
4 or 5 out of the 8 individual genes (Figure 3B). Analysis of a larger dataset (Taylor et al., 
2010) for concurrent expression of the 8 glycosylation enzymes found 18 significant 
associations (Figure 3C), suggesting that changes in glycosylation gene expression in PCa 
generally co-occur for several genes in parallel within tumours.  
 
Androgens control expression of O-glycosylation and core synthesis enzymes that 
are essential for viability of PCa cells 
The above data indicates that androgens control the gene expression of at the 
transcriptional level of enzymes operating at multiple steps within the glycosylation synthetic 
pathways. We next tested whether this set of 8 individual glycosylation enzymes are 
upregulated by androgens at the protein level, and whether these enzymes are functionally 
important in prostate cancer cells. Three glycosylation enzyme genes, GALNT7, 
ST6GalNAC1 and GCNT1 map to the O-glycosylation pathway (Figure 4A). Initiation of O-
glycosylation is carried out by a family of GALNT sialyltransferase enzymes, including 
GALNT7, which catalyse the transfer of GalNAc to serine and threonine residues on target 
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proteins to produce the Tn antigen (Ten Hagen et al., 2003). The Tn antigen can be modified 
by ST6GalNAc1 to produce the truncated cancer-associated sTn antigen (Sewell et al., 
2006, Munkley, 2016b), or can be converted to core 1 O-glycan structures. Core 1 or the T 
antigen is then converted to core 2 by one of three core 2 enzymes (GCNT1,2 and 3). We 
previously showed that ST6GalNAc1 and the sialyl-Tn (sTn) cancer-associated antigen it 
produces are directly regulated by androgens in PCa cells (Munkley et al., 2015c, Munkley 
and Elliott, 2016b). Here, in addition to androgen regulation of ST6GalNAc1,we additionally 
show androgen control of the O-glycosylation enzymes GALNT7 and GCNT1 (4B, upper 
panel). Furthermore and consistent with these enzymes being under control of the androgen 
receptor, protein induction in response to androgen treatment was blocked by siRNA 
mediated depletion of the AR (Figure 4B, lower panel). GCNT1 is important for formation of 
core 2 branched O-glycans and has been implicated in synthesis of the cancer-associated 
Sialyl Lewis X (SLeX) antigen (Chen et al., 2014). As well as upregulation of GCNT1, we also 
observed increased expression of SLeX in PCa cells in response to androgen stimulation 
(Figure 4C, Supplementary Figure 4), indicating that androgen control of GCNT1 is likely to 
be an important regulatory step in this glycan synthetic pathway. We also found that in both 
LNCaP and VCaP cells that androgen exposure leads to up-regulated expression of the core 
1 Thomsen-Friedenreich antigen (T-antigen, detected by PNA lectin), which is produced by 
the GALNT7 enzyme. Also consistent with an up-regulation of core 1 glycans in PCa cells 
exposed to androgens, we observed an increased binding of the soluble lectin Galectin-3, 
which binds core 1 glycans (Newlaczyl and Yu, 2011)(Figure 4C, Supplementary Figure 4). 
To test whether changes in the expression of GALNT7 and GCNT1 contribute to PCa 
viability, we individually depleted cells of these enzymes using siRNAs. Loss of both 
enzymes resulted in a significant reduction in cell number and significantly reduced cell 
viability 96 hours after siRNA treatment, in comparison to cells treated with the control siRNA 
(p<0.02, Figure 4D and Supplementary Figures 5&6). Taken together, our data suggests 
that the O-glycosylation and core synthesis enzymes GALNT7, ST6GalNAC1 and GCNT1 
are induced by androgens in PCa cells at the protein level, and that production of these 
enzymes could be important for the synthesis of important cancer-associated O-glycans and 
contribute to PCacell viability.Essential enzymes within the O-GlcNAcylation pathway 
are controlled by androgens in PCa cells 
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The identity of the core set of 8 androgen regulated glycosylation enzymes identified above 
also suggest that the hexosamine biosynthesis pathway (HBP) is under more extensive 
androgen control in PCa cells than previously realised. The HBP produces an amino-sugar 
conjugate UDP-N-acetylglucoamine (UDP-GlcNAc), which provides a substrate for 
posttranslational modification of proteins (Wellen et al., 2010) (Figure 5A). While it was 
previously known that the HBP enzyme UAP1 is directly regulated by androgens in PCa 
cells (Itkonen et al., 2014), our reciprocal analysis demonstrated that the PGM3 enzyme is 
also androgen-regulated via the AR (Figure 2 and 5B).  
Further supporting the hypothesis that the glycans produced by the HBP are also 
under androgen control, we detected increased O-GlcNAc in PCa cells exposed to 
androgens (detected by a glycosylation specific antibody and two glycan specific lectins, 
Figure 5C and Supplementary Figure 4).  Depletion of either UAP1 or PGM3 with two 
independent siRNAs significantly reduced cell viability of both LNCaP and CWR22Rv1 cells 
in comparison to cells treated with the control siRNA, consistent with expression of both 
these enzymes being important for prostate cancer cell survival (Figure 5D, Supplementary 
Figures 5&6). 
 
Androgens control synthesis of chondroitin sulphate in PCa cells  
The identity of the core set of 8 androgen regulated genes we identified by our reciprocal 
analysis further predicted that synthesis of chondroitin sulphate (CS) is under androgen 
control in PCa cells, via activation of CSGalNacT1 expression. While six 
glycosyltransferases are involved in CS synthesis, the enzyme chondroitin sulphate N-
acetylgalactosaminyltransferase 1 (CSGalNAcT1) is involved in the initiation and elongation 
processes (Sakai et al., 2007, Watanabe et al., 2010) (Figure 6A). We confirmed androgen 
regulation of CSGalNacT1 expression in LNCaP and VCaP cells (Figure 6B,C and 
Supplementary Figure 4). In PCa cells treated with androgens we found increased CS 
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synthesis, indicating that CSGalNacT1 is likely to be a key control point for synthesis of this 
CS glycan (Figure 6D left panels). CS forms the GAG side chains of several proteoglycan 
families, including the PCa associated large CS proteoglycan, Versican. Consistent with 
previous reports, we also found that the Versican is regulated by androgens in PCa cells 
(Read et al., 2007) (Figure 6D right panel). Depletion of CSGalNAcT1 using two different 
siRNAs very dramatically reduced CSGALNACT1 mRNA expression as monitored by qPCR. 
Decreased expression of CSGALNACT1 also increased the numbers of dead and apoptotic 
cells, and significantly decreased cell viability in both LNCaP and CWR22Rv1 cells in 
comparison to cells treated with the control siRNA, suggesting a key role for the 
CSGALNACT1 enzyme in PCa cell biology (Figure 6E and Supplementary Figures 5&6).  
 
N-glycan modifications are controlled by androgens in prostate cancer cells 
Our data further predicted that that N-glycan synthesis is also under androgen control in PCa 
cells, via expression control of the ST6GAL1 and EDEM3 genes. ST6GAL1 encodes a 
sialyltransferase that catalyses the transfer of sialic acid onto terminal galactose containing 
N-glycan substrates (Schultz et al., 2013, Hedlund et al., 2008) (Figure 7A). We confirmed 
expression of ST6GAL1 protein is regulated by androgens in PCa cells by western blot 
(Figure 7B). While we observed an increase in ST6GAL1 expression in both LNCaP and 
VCaP cells in response to androgen stimulation, there was no corresponding increase in 
sialylation of terminal N-glycans detected by SNA binding (Figure 7Ci and Supplementary 
Figure 4) suggesting the influence of this enzyme on terminal sialylation may be dependent 
upon cellular background. Supporting such a model, expression of ST6GAL1 in DU145 PCa 
cells did increase SNA binding (Figure 7Cii). Although it did not detectably increase 
sialylation of terminal N-glycans, depletion of ST6GAL1 using two different siRNAs led to 
reduced cell viability in both LNCaP and CWR22Rv1 cells (Figure 7D and Supplementary 
Figures 5&6) indicating ST6GAL1 has an important biological role in these cell lines.  
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EDEM3 stimulates mannose trimming of N-glycans from total glycoproteins, and also 
enhances glycoprotein endoplasmic reticulum-associated degradation (ERAD) of misfolded 
glycoproteins (Hirao et al., 2006, Olivari and Molinari, 2007) (Figure 7A), which is particularly 
important in the context of cancer where increased metabolic needs lead to the 
accumulation of faulty proteins (Olzmann et al., 2013). We confirmed androgen regulation of 
EDEM3 protein expression in PCa cells (Figure 7B). Consistent with this we also found that 
an increase in branched N-glycans (detected by ConA lectin) in response to androgen 
treatment (Figure 7Ciii). siRNA depletion experiments with two independent siRNAs showed 
that expression of EDEM3 enzyme is important for PCa cell viability and growth (Figure 7E 
and Supplementary Figures 5&6). 
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Discussion  
Although aberrant glycosylation is common in cancer and has been linked to PCa 
progression (Munkley et al., 2016), our understanding of what drives these cancer 
associated glycan changes has been scant and has relied upon anecdotal observations. 
Here, using a global transcriptomic analysis to identify genes that have a reciprocal 
expression signature between androgen deprivation therapy in patients and androgen 
stimulation in culture, we identify glycosylation as a cohesive enriched pathway that is under 
extensive control by androgen hormones. A total of 31 genes encoding glycosylation 
enzymes were revealed through reciprocal expression signatures, and of these we further 
identify a core set of 8 androgen regulated glycosylation enzymes that are also significantly 
up-regulated in multiple cohorts of clinical PCa material. Significantly, only two of these 8 
genes, ST6GalNAc1 and UAP1, have previously been identified to have roles in clinical PCa 
(Munkley et al., 2015c, Itkonen et al., 2014). The remaining 6 genes are identified as 
androgen regulated by our dataset, and reveal new control points through which these 
glycan synthesis pathways can be regulated in cells, and new mechanisms through which 
androgens regulate the behaviour of PCa cells. We find each of these 8 glycosylation 
enzymes are important for PCa cell viability, suggesting that loss of these enzymes in 
response to ADT might make an important and previously unknown contribution to tumour 
regression in patients. 
Glycosylated proteins and other glycoconjugates are major cellular components 
which have been causally associated with all of the hallmarks of cancer (Munkley and Elliott, 
2016a). Altered activity or expression of glycosylation enzymes in cancer cells can lead to 
glycan modifications to alter cell-cell adhesion, migration, interactions with the cell matrix, 
immune surveillance, signalling and cellular metabolism and may modify these processes in 
PCa (Munkley et al., 2016). Glycosylation pathways produce glycan structures via the 
cumulative enzymatic activity of many glycosylation enzymes. The core set of 8 androgen 
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regulated glycosylation genes that we identify here belong to the O-glycan, HBP, chondroitin 
sulphate, and N-glycan synthetic pathways that are already known to be important in cancer.  
O-glycans are altered in the early stages of cellular transformation, and are important 
for cancer initiation, invasion and metastasis (Pinho and Reis, 2015). We showed previously 
that induction of the O-glycosylation enzyme ST6GalNAc1 by androgens in prostate cancer 
cells can reduce prostate cancer cell adhesion (Munkley et al., 2015c, Munkley and Elliott, 
2016b). In this study we confirm androgen regulation of ST6GalNAc1 and show for the first 
time a link between androgens and two additional O-glycosylation enzymes in prostate 
cancer, GALNT7 and GCNT1. Expression of GALNT7 has previously been found to be up-
regulated in several cancer types, including PCa (Chen et al., 2014, Li et al., 2014, Peng et 
al., 2012, Gaziel-Sovran et al., 2011), and is linked to metastasis and invasion in 
nasopharyngeal carcinoma (Nie et al., 2015). As GALNT7 initiates O-glycosylation to 
produce the Tn antigen, upregulation of this enzyme could potentially be linked to a range of 
changes in O-glycans in prostate cancer cells. The Tn antigen can be further modified by 
ST6GalNAc1 to produce sTn raising the possibility for a role for GALNT7 in the expression 
of this important cancer associated antigen. GALNT7 may also have a role in the synthesis 
of the T-antigen, which is frequently over-expressed in cancer (Hanisch and Baldus, 1997, 
Cazet et al., 2010, Springer, 1984) and is associated with the adhesion of PCa cells to the 
endothelium (Glinsky et al., 2001). In cancer, truncated O-glycans often recruit carbohydrate 
binding proteins, or lectins that can play a key role in disease progression and metastasis 
(Munkley, 2016a). Here we show increased binding of Galectin-3 in prostate cancer cells 
treated with androgens. These results are important, as Galectin-3 has been implicated in 
PCa tumor growth, and suggested as a potential therapeutic target (Wang et al., 2009b). Our 
data are also the first to suggest a link between the AR and expression of GCNT1 in prostate 
cancer. Increased GCNT1 expression has already been linked to PCa progression, shown to 
increase prostate tumor growth in vivo, and been implicated in synthesis of the cancer-
associated SLeX antigen (Chen et al., 2014, Hagisawa et al., 2005, Kojima et al., 2015). 
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Here, we show for the first time that expression of both GCNT1 and the SLeX  antigen are 
regulated by androgens in prostate cancer cells. SLeX is a major sialylated antigen 
associated with poor prognosis and metastasis in PCa, and has been detected on PSA and 
MUC1 proteins from patients with PCa (Chen et al., 2014).  
Multiple levels of evidence presented here also suggest that in addition to the O-
glycan pathway, three other major glycosylation pathways important in PCa are under the 
control of androgens. Firstly, one of these pathways is the HBP, which creates the amino-
sugar conjugate O-GlcNAc which is known to be elevated in PCa (Kamigaito et al., 2014). O-
GlcNAc is so important it has been suggested as a new hallmark of cancer (Fardini et al., 
2013). Our data shows that expression levels of the two final two enzymes in the HBP are 
controlled by androgens, as is the expression of the O-GlcNAc glycan itself. Secondly, we 
also detect androgen regulation of the pathway producing chondroitin sulphate (CS) and of 
CS itself, which is a type of GAG (glycosaminoglycan) present in extracellular matrices and 
on the surface of many cell types (Gandhi and Mancera, 2008). CS is increased in 
metastatic PCa (Ricciardelli et al., 2009a, Ricciardelli et al., 1997), where it is thought to play 
a role in cellular proliferation and differentiation (Hardingham and Fosang, 1992). Expression 
of the large CS proteoglycan Versican, which is linked to cell adhesion and associated with 
poor outcomes in many different cancers including PCa (Ricciardelli et al., 2009b), also 
responds to androgens.  
Thirdly, we also find that androgens control production of two key enzymes involved 
in N-glycan processing; ST6GAL1 and EDEM3. ST6GAl1 is important for controlling 
sialylation of N-terminal glycans, and is over-expressed in many types of cancer (Swindall et 
al., 2013). Altered sialylation has long been associated with cancer cell metastasis, invasion 
and survival (Pinho and Reis, 2015, Munkley, 2016a). Expression of ST6GAL1 is already 
linked to the epithelial-mesenchymal transition (EMT) and malignancy (Lu et al., 2014), but 
the mechanisms driving these changes remain poorly understood. EDEM3 controls 
mannose trimming of N-glycans, and has previously been shown to be upregulated in 
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malignant PCa as part of a glycosylation gene signature (Chen et al., 2014). β1,6GlcNAc tri/ 
tetra branched N-glycans and cryptic N-glycans are detected in PCa and have been linked to 
metastasis and are being investigated as potential biomarkers (Ishibashi et al., 2014, Wang 
et al., 2013). It is possible that the elevated levels of EDEM3 plays a role in creating these 
aberrant N-glycans.  
PCa is a unique and confounding disease, characterised by prognostic heterogeneity 
and there is a key clinical need to develop biomarkers to help distinguish indolent from 
aggressive disease, as well as to develop new treatments for advanced PCa.  Our study 
identifying glycosylation as an androgen-regulated process in PCa has important clinical 
implications both diagnostically and therapeutically. The most widely used serological 
biomarkers for cancer diagnosis and monitoring are glycoproteins, and monitoring the glycan 
composition of specific glycoproteins can dramatically increase their specificity as 
biomarkers (Reis et al., 2010). Numerous studies have examined whether a tumour specific 
glycan signature on prostate specific antigen (PSA) can be used to distinguish between BPH 
and PCa (Gilgunn et al., 2013) and there are ongoing studies analysing the glycan 
composition of serum, plasma, exosomes,  expressed-prostatic secretions (EPS) fluids and 
formalin-fixed, paraffin-embedded (FFPE) tissues to diagnose PCa and determine prognosis 
(Yoneyama et al., 2014, Kyselova et al., 2007, Drake and Kislinger, 2014, Powers et al., 
2013, Powers et al., 2014, Drake et al., 2015).  Our study identifies a panel of glycosylation 
enzymes and their corresponding antigens as potentially important in prostate cancer. An 
increased understanding of how glycosylation influences prostate cancer cell behaviour 
should aid in the development of glycosylation specific biomarkers for use in the early 
detection and management of PCa. Glycans also likely play roles in all aspects of cancer 
progression and are therefore attractive targets for therapeutic intervention (Munkley and 
Elliott, 2016a). Previous work has shown that inhibiting glycosylation, even in conditions 
where the AR is active, can reduce PCa cell viability (Itkonen and Mills, 2013). An increased 
understanding of how glycosylation modulates the biological function of prostate cancer cells 
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will allow the development of a relatively unexploited field of drugs based on inhibitors, 
glycan antagonists and glycan function modulators.   
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Figure Legends 
 
Figure 1: Reciprocal gene expression signatures identify a core set of clinically 
relevant androgen-regulated target genes. (A) RNA-Seq expression analysis of LNCaP 
cells treated with or without 10nM R1881 (a synthetic androgen) for 24 hours in triplicate, 
and of 7 PCa patient prostate biopsies before and after androgen ablation therapy (ADT). 
Venn diagrams show the number of genes with significant differential expression (q<0.05). 
Comparison of the two RNA-Seq datasets identified approximately 700 androgen-regulated 
genes with reciprocal regulation. 559 genes were up-regulated by androgen treatment in 
LNCaP cells, but down-regulated in PCa patient samples following ADT (upper Venn 
diagram). Conversely, 115 genes were down-regulated by androgen addition in LNCaP 
cells, but up-regulated in PCa patient samples following ADT (lower Venn diagram). (B) 
Scatter plot of reciprocally regulated genes between the two datasets. The X coordinates are 
expression log2 fold change values of individual genes in LNCaP cells treated with 
androgens, relative to cells grown in steroid deplete media. The Y coordinates are log2 fold 
changes in gene expression of individual genes in the patient dataset after ADT, relative to 
expression values before treatment. The log2 fold changes were calculated using the 
relative FPKM values for each gene. (C) Gene Ontology (GO) analysis of the reciprocally 
regulated genes identified 72 terms with significant gene enrichment (p<0.05). The top 15 
significantly enriched terms are shown in the graph.  
 
Figure 2: Thirty one glycosylation enzymes are regulated by androgens in PCa cells. 
The term ‘glycosylation’ was contained in 7 significantly enriched GO terms.  (A) Real-time 
PCR validation of 31 androgen-regulated glycosylation related genes identified by GO 
analyses. LNCaP cells were grown in triplicate either with or without 10nM R1881 
(androgens) for 24 hours. The Y axis shows the relative expression changes for each gene 
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with androgens. These 31 glycosylation enzymes were significantly down-regulated in 7 PCa 
patients following ADT (B). The Y axis shows the relative expression level for each gene 
(calculated by comparing the FPKM expression values of genes after ADT to the value 
before treatment). Our meta-analysis of clinical PCa gene expression datasets identified 8 
glycosylation enzymes, which were significantly (p<0.05) upregulated in PCa relative to 
normal prostate tissue (Supplementary Table 7). (C) Real-time PCR analysis of glycosylation 
genes in LNCaP cells treated with or without androgens (10nM R1881) over a 24 hour 
period.  
 
Figure 3: Core glycosylation gene signatures in clinical PCa RNA datasets.  Meta-
analysis of clinical RNA datasets identified 8 glycosylation enzymes with significant 
upregulation in PCa tissue (Supplementary Table 7).  (A) Real-time PCR analysis of the 
expression of UAP1, GCNT1, GALNT7, ST6GAL1, PGM3, EDEM3 and CSGALNACT1 in an 
independent clinical RNA dataset (BPH v carcinoma, clinical cohort B). Expression of 
ST6GALNAC1 mRNA was analysed in these samples previously (Munkley et al., 2015c).  
The CAMKK2 gene was used as a control. (B) Real-time PCR analysis of the expression of 
all 8 glycosylation enzymes in matched normal and tumor tissue samples from 9 patients 
(clinical cohort C) to monitor expression of individual genes in parallel in individual patients. 
Upregulated genes are shown in red, downregulated genes in blue, and genes not changing 
expression in grey (a significant gene expression change is recorded as >1.6 fold change 
relative to 3 reference genes). Grey indicates there was no significant change in gene 
expression in PCa relative to a matched normal control. Red indicates significant mRNA 
upregulation, and blue indicates significant mRNA downregulation. The bar chart to the right 
shows that most patients show a pattern where more than one of the core glycosylation 
genes increase expression, with typically 4 genes changing expression concurrently. (C) 
Analysis of glycosylation enzyme mRNA expression in 113 primary prostate cancer tissues 
(Taylor et al., 2010) indicates significant concurrent up-regulation of 18 (out of a possible 28)  
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gene pairs (p values were derived from exact Fisher tests, p<0.05). Red indicates significant 
mRNA upregulation, and blue indicates significant mRNA downregulation. The bar chart to 
the right shows that in most patients glycosylation enzyme enzymes tend to be upregulated 
concurrently with 4-5 other enzymes. 
 
Figure 4: Androgens control expression of O-glycosylation and core synthesis 
enzymes, controlling synthesis of the sTn and SLeX antigens. (A) Overview of the 
catalytic roles GALNT7, ST6GalNAc1 and GCNT1 play in the initiation of O-glycosylation 
and core synthesis. (B) Western blot analysis of ST6GalNAc1, GALNT7 and GCNT1 
enzymes in LNCaP cells grown with 10nM R1881 (androgens, A+) or without (steroid 
deplete, SD) for 24 or 48 hours. Androgen-regulation of each glycosylation enzyme was 
confirmed using esiRNA mediated depletion of the AR. Actin was used as a loading control. 
The specificity of each antibody used was confirmed by detection of siRNA mediated protein 
depletion (Supplementary Figure 1). (C) Detection of cancer-associated O-glycans in PCa 
cells, using glycosylation specific antibodies and fluorescently labelled lectins with binding 
specificities to selected sugar moieties. LNCaP cells grown with 10nM R1881 (androgens) or 
without (steroid deplete) for 72 hours were labelled with antibodies specific to the glycans 
shown. A comparison of the images shows that androgens induce dramatic differences in 
the glycan composition of PCa cells. Consistent with previous data (Munkley et al., 2015c), 
exposure to androgens upregulate the expression of the cancer-associated sialyl-Tn antigen 
(sTn). Androgen treatment also upregulates expression of core 1 structures (detected by 
PNA lectin and Galectin-3 binding) and expression of the Sialyl Lewis X antigen (SLeX). Bar 
is 10µM. Similar changes in glycan signatures in response to androgen stimulation were also 
observed in androgen-responsive VCaP prostate cancer cells (Supplementary Figure 4). (D) 
GALNT7 and GCNT1 expression is needed for PCa cell viability. For each enzyme siRNA-
mediated protein depletion was carried out using two different siRNAs in LNCaP cells grown 
in full media, and confirmed by western blot after 72h. 96h after transfection the relative 
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number of live cells was calculated. Representative crystal violet stained images are shown 
below. Further details are given in Supplementary Figure 5.  
 
Figure 5: Essential enzymes within the O-GlcNAcylation pathway are controlled by 
androgens in PCa cells.  (A) The hexosamine biosynthetic pathway (HBP) catalyses the 
formation of UDP-GlcNAc and culminates in the attachment of O-GlcNAc onto 
serine/threonine residues of target proteins. HBP enzymes regulated by androgens in 
prostate cancer cells are shown in red. (B) Western blot analysis of UAP1 and PGM3 
enzymes in LNCaP cells grown with 10nM R1881 (androgens) or without (steroid deplete) 
for 24 or 48 hours. Androgen-regulation of each glycosylation enzyme was confirmed using 
esiRNA mediated depletion of the AR. Actin expression was monitored as the loading 
control. The specificity of each antibody used was confirmed by detection of siRNA mediated 
protein depletion (Supplementary Figure 1). (C) Detection of O-GlcNAcylation in PCa cells, 
using a glycosylation-specific antibody and fluorescently labelled lectins with binding 
specificities to O-GlcNAc. LNCaP cells were grown with 10nM R1881 (androgens) or without 
(steroid deplete) for 72h prior to fixation and labelling. A comparison of the images shows 
that androgens induce an increase in O-GlcNAc in prostate cancer cells. The size bar 
represents 10µM. Similar changes in O-GlcNAc expression were also seen in androgen-
responsive VCaP prostate cancer cells (Supplementary Figure 4). (D) UAP1 and PGM3 
influence PCa cell growth and viability in vitro. For each enzyme siRNA-mediated protein 
depletion was carried out using two different siRNAs in LNCaP cells grown in full media, and 
confirmed by western blot after 72h. The relative number of live cells at 96h after transfection 
was calculated relative to a control non-targeting siRNA. Representative crystal violet 
stained images are shown below. Further details are given in Supplementary Figure 5.  
Figure 6: Androgens control synthesis of chondroitin sulphate in PCa cells. (A) 
Initiation of chondroitin sulphate (CS) synthesis is mediated by two enzymes, CSGalNAcT1 
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and CSGalNAcT2, of which CSGalNAcT1 is androgen regulated (shown in red).  (B) Real-
time PCR analysis of CSGalNAcT1 mRNA over a range of concentrations of R1881 
(androgens) in LNCaP cells. (C) Real-time PCR analysis of CSGalNAcT1 mRNA in LNCaP 
cells treated with the AR antagonist CasodexR in the presence of 10nM R1881. (D) 
Detection of both CS and the CS proteoglycan versican in PCa cells grown with or without 
androgens (10nM R1881) for 72 hours. Androgen-regulation of the enzyme is for 
CSGalNAcT1 confirmed at the mRNA level only (we were unable to obtain an antibody 
against the human CSGalNAcT1 protein which worked in our hands). The size bar is 
equivalent to 10µM. Similar changes were also seen in VCaP prostate cancer cells 
(Supplementary Figure 4). (E) siRNA-mediated protein depletion of CSGalNAcT1 in LNCaP 
cells grown in full media using two different siRNAs was confirmed by real-time PCR after 
72h (upper left panel).  The relative number of live, dead and apoptotic cells 96 hours after 
transfection was calculated for each siRNA relative to a control non-targeting siRNA using 
flow cytometry. Representative crystal violet stained images are shown below.  
 
Figure 7: N-glycan modifications are controlled by androgens in prostate cancer cells. 
(A) ST6GAL1 is a sialytransferase which catalyses the addition of terminal sialic acid 
residues onto N-glycans. EDEM3 mediates the trimming of N-glycans, which are then further 
modified by other enzymes. (B) Western blot analysis of ST6GAL1 and EDEM3 in LNCaP 
cells grown with 10nM R1881 (androgens) or without (steroid deplete) for 24 or 48 hours. 
Androgen-regulation of ST6GAL1 and EDEM3 was confirmed using esiRNA mediated 
depletion of the AR, which blocks up-regulation of both proteins. GAPDH was used as a 
loading control. (C) (i) Detection of sialic acid in LNCaP cells grown with or without 
androgens for 72 hours, and in (ii) DU145 cells over-expressing either EV control or 
ST6GAL1 using SNA lectin. Although overall sialic acid expression did not increase with 
exposure to androgens in LNCaP cells, over-expression of ST6GAL1 in DU145 cells does 
result in an increase. (iii) Detection of branched N-glycans in LNCaP cells using fluorescently 
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labelled ConA lectin. Cells treated with androgens (10nM R1881) for 72h have increased 
ConA binding relative to cells grown without androgens (steroid deplete).  (D,E) siRNA-
mediated protein depletion of ST6GAL1 and EDEM3 in LNCaP cells grown in full media 
using two different siRNAs was confirmed by western blot after 72h. The relative number of 
live, dead and apoptotic cells 96 hours after transfection was relative to a control non-
targeting siRNA using flow cytometry (upper right panels). Representative crystal violet 
stained images are shown below.  
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